Evidence map›Paper›PMID 42816667›Full record

ArticleBreast cancer research and treatment2026

Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability.

Shivahamy Maheswaran, Aylin S Dedeoglu, Andrzej Niemierko, Rachel O Abelman, Rachel Jimenez, Olivia Rieur, Jennifer Hutchinson, Neelima Vidula, Laura M Spring, Leif W Ellisen and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shivahamy MaheswaranDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Aylin S DedeogluMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Andrzej NiemierkoMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Rachel O AbelmanMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Rachel JimenezMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Olivia RieurMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jennifer HutchinsonMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Neelima VidulaMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Laura M SpringMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Leif W EllisenMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Steven J IsakoffMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Seth A WanderMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Aditya BardiaMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Arielle J MedfordMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA. amedford@mgh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOptimizing metaplastic breast cancer (MpBC) management remains an unmet clinical need. Current literature on MpBC response toantibody drug-conjugates is limited to individual case reports and case series. This study investigates outcomes in metastatic MpBC treated withsacituzumab govitecan (SG) and characterizes actionable targets to inform future studies.

methodsPatients (pts) with metastatic triple negative breastcancer (TNBC) treated at the Massachusetts General Hospital Cancer Center between 2000 and 2025 were assessed for MpBC and receipt of SG. MpBCcases were interrogated for biomarkers qualifying for targeted therapy: HER2-low status (IHC 1+/2+), combined positive score (CPS), and targetablegenomic variants based on next-generation sequencing of plasma and/or tissue ordered by the treating provider. Multivariable Cox regression analysisassessed the association of MpBC under SG treatment with progression-free survival (PFS) and overall survival.

resultsMpBC cases (n = 17) had anumerically shorter median PFS under SG compared to non-MpBC TNBC (n = 133) [2.6 vs. 6.8 months, p = 0.16]. While most patients with MpBC hadlimited response to SG monotherapy, two patients on SG + talazoparib had prolonged PFS. Annotation of available genomic and pathology data from allpatients with MpBC (n = 58) revealed targetable alterations including 34/56 patients with HER2-low status, 8/45 patients with germline BRCA1/2mut, and9/30 patients with somatic PIK3CAmut. MpBC response to matched therapies showed variable PFS.

conclusionTo our knowledge, this study is one ofthe largest analyses of MpBC response to SG and highlights challenges of treating rare diseases at large. Multi-institutional collaboration and inclusive trialdesign are essential to optimize treatments for MpBC.

Indexed as

Antibodies, Monoclonal, HumanizedBiomarkers, TumorCamptothecinTriple Negative Breast NeoplasmsAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoconjugatesMetaplasiaMiddle AgedMolecular Targeted TherapyNeoplasm MetastasisTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkers, TumorCamptothecinErb-b2 Receptor Tyrosine KinasesImmunoconjugatessacituzumab govitecanAntibody–drug conjugatesGenomic profilingMetaplastic breast cancerSacituzumab govitecanTriple-negative breast cancer

Identifiers

PMID42816667

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.